US FDA rejects closely watched lung cancer drug from China
Resumen detallado
US FDA rejects closely watched lung cancer drug ivonescimab from China after trial failed to show a survival benefit. Read more at straitstimes.com.
The US Food and Drug Administration said the global clinical trial had not shown a statistically significant extension in patients’ lives.
The US Food and Drug Administration (FDA) rejected a first-of-its-kind cancer drug that was invented in China, a setback for a medicine that had become a symbol of China’s ascendance as a powerhouse in drug development.
Summit Therapeutics, the Florida company that has been seeking to bring the drug to the US market, disclosed the agency’s decision in a news release on Nov 15. Summit bought the US rights to the drug from Akeso Biopharma, a Chinese drugmaker that invented the drug in its laboratories and sells it in China.
Inicio del artículo, extracto de The Straits Times. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.straitstimes.com)



